Read More Analyst Ratings News Price Target Reiteration Needham Reiterates Buy on Engagesmart, Maintains $40 Price Target By Benzinga Newsdesk February 10, 7:06 AM Needham analyst Scott Berg reiterates Engagesmart (NYSE:ESMT) with a Buy and maintains $40 price target. ESMT
Read More Legal News Elon Musk Lawyers Say Twitter Won’t Accept Renewed $44B Bid For The Company, Ask Delaware Court To Halt Upcoming Trial – By Benzinga Newsdesk October 6, 3:55 PM - Twitter Source Citing AP News TWTR
Read More Biotech Exclusives General Health Care Market-Moving Exclusives News Penny Stocks Top Stories EXCLUSIVE: SAB Biotherapeutics’ Influenza Immunotherapy Shows Safety, Efficacy In Early-Stage Trials By Vandana Singh May 4, 8:00 AM SAB Biotherapeutics Inc (NASDAQ: SABS) has announced the presentation of safety and efficacy data from Phase 1 and 2a trials of its influenza immunotherapy, SAB-176. RHHBY
Read More Commodities Earnings Eurozone Global Intraday Update Markets News Penny Stocks Small Cap Nasdaq Down Over 1%; Crude Oil Rises Sharply By Lisa Levin August 29, 12:02 PM U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Monday. AHI